Iter Investments

www.iterinvestments.com

VCMatch tracks Iter Investments as an investor focused on Biotech, Pharma, and Digital Health companies and Pre-Seed and Seed rounds. Upload your deck to compare your startup against the full private matching profile.

Check Size

Not specified

Stages

Pre-Seed, Seed, Series A

Focus Areas

Biotech, Pharma, Digital Health

Geography

Not specified

Investment Thesis

Iter Investments pursues early-stage, cross-sector investments across the alternative therapeutics value chain to commercialize novel compounds, technologies, and delivery models that can “revolutionize mental and behavioral health.” The firm argues there is a convergence of medical research, regulatory change and public awareness creating the largest emerging market in mental health and believes “the current funding gap for early-stage companies presents an attractive investment opportunity.” Iter couples capital deployment with active operational, regulatory and advocacy support via a team of builders, scientists, clinicians, lawyers and operators to accelerate portfolio companies toward commercialization and mainstream integration.

Is Iter Investments right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Iter Investments is most relevant for founders raising Pre-Seed, Seed, and Series A rounds in Biotech, Pharma, Digital Health, and Medtech.

Focus statement

Iter Investments is a venture capital firm focused on supporting emerging companies within the ecosystem of developing innovative alternative therapeutics to address the underserved mental and behavioral health sectors.

Value Add

Cross-functional founding team: “builders, investors, lawyers, scientists, physicians, clinicians, and technologists” who cover end-to-end value chain capabilities for sourcing, diligence and portfolio management.
Vertical breadth across the alternative therapeutics ecosystem — early-stage investments in drug development, manufacturing (e.g., Psygen), clinics, digital therapeutics, training/education, data and media (Nucleus Holding).
Ownership of Nucleus Holding (media and data assets) to generate proprietary deal flow and ecosystem insights (Psychedelic Invest, Neuly).
Active advocacy and regulatory engagement: the firm’s team holds leadership roles in non-profits (e.g., Mr. Psychedelic Law, MindArmy) and states they are “actively participating in legal reform, advocacy, and community building.”
Hands-on commercialization expertise with clinical, regulatory and IP leaders (FDA lead, clinical lead, commercialization lead, IP lead) embedded in the team to de-risk development and market entry.